Cell-cycle pathway impairments resulting in CDK4 and 6 activation are frequently observed
in human papillomavirus (HPV)-negative squamous cell carcinoma of the head and neck …

Simple Summary We previously showed that ribociclib induces cell cycle arrest in some
human papillomavirus (HPV)-negative squamous cell carcinomas of the head and neck …

Background: The majority of human papillomavirus (HPV)-negative squamous cell
carcinoma of the head and neck (SCCHN) present upregulation of the epidermal growth …

Ribociclib is a specific cyclin dependent kinase (Cdk) 4/6 inhibitor that induces G1 arrest by
blocking the formation of cyclin D1-Cdk4/6 complex and inhibiting retinoblastoma (RB) …

The loss of p16 is a signature event in Human Papilloma Virus (HPV)-negative head and
neck squamous cell carcinoma (HNSCC) that leads to increased Cyclin Dependent Kinase …

Objective Lack of effective therapies remains a problem in the treatment of oral squamous
cell carcinoma (OSCC), especially in patients with advanced tumors. OSCC development is …

Background Deregulation of cell-cycle pathway is ubiquitously observed in human
papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC) …

Preclinical data support investigation of selective CDK4/6 inhibition as a therapeutic strategy
for human papillomavirus (HPV)–unrelated head and neck squamous cell carcinoma …

Inhibition of CDK4/6 represents a new potential treatment for HPV-negative SCCHN
patients. Randomized clinical trials that investigate these compounds in an unbiased …

Objectives To test the safety of the CDK4/6 inhibitor palbociclib with cetuximab in patients
with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Materials and …